Literatur
Nayak L et al. Blood. 2017;129(23):3071–73.
Korfel A et al. J Clin Oncol. 2016;34(15):1757–63.
Kasenda B et al. Leukemia. 2017; https://doi.org/10.1038/leu.2017.170.
Berghoff AS et al. Clin Neuropathol. 2014;33(1):42–9.
Chapuy B et al. Blood. 2016;127(7):869–81.
Cortazar FB et al. Kidney Int. 2016;90(3):638–47.
Houillier C et al. Neurology. 2015;84(3):325–6.
Rubenstein J et al. J Clin Oncol. 2017;34(15, Suppl):7502.
Ghesquieres H et al. Blood 2016;128(22):785.
Korfel A et al. J Clin Oncol. 2016;34(15):1757–63.
Grommes C et al. Cancer Discov. 2017;7(9):1018–29.
Choquet S et al. Blood 2016;128(22):784.
Lionakis MS et al. Cancer Cell. 2017;31(6):833–843.e5.
Originalie
Nayak L et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129(23):3071–73.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Korfel, A. Hinweise auf die Wirksamkeit der Checkpointblockade beim ZNS-Lymphom. Info Onkol. 20, 10–12 (2017). https://doi.org/10.1007/s15004-017-5841-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15004-017-5841-2